Flagship Biosciences appoints Gina Wallar, Ph.D., MPH as new Chief Commercial Officer

Scientist turned business leader will strengthen the company’s commercial operations and bolster business development efforts.

BROOMFIELD, CO – March 9, 2023Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the appointment of Gina Wallar, Ph.D, MPH as their new Chief Commercial Officer. Gina is an accomplished business executive in the pharma services and diagnostics industry with 20 years’ experience leading international sales teams, managing people, and spearheading business development from a financial perspective.

“We are very excited to have Gina join the Flagship team. Gina brings over 20 years of experience in commercial, operational, and scientific expertise, having held leadership positions at several large, commercial organizations,” said CEO Trevor Johnson. “Flagship is a company dedicated to the best science, and her passions for both science and business make her the perfect choice for our CCO.”

Prior to joining Flagship Biosciences, Dr. Wallar acted as Senior Vice President for Fulgent Genetics where she led their sales and business development efforts. Prior to that, Dr. Wallar held numerous positions at Neogenomics Laboratories from 2014-2022, most recently having acted as their President of Pharma Services. She also held leadership roles in the Clinical Division and as Director of Scientific Affairs and Project Management. For 12 years (from 2002-2014), Dr. Wallar served as the Director for LabCorp Clinical Trials in Los Angeles, CA and oversaw PD-L1 testing, supporting the first companion diagnostic approval.

Dr. Wallar earned her PhD at UCLA in molecular epidemiology with her field of study on risk susceptibility polymorphisms in the cancer stem cell pathway. She has an MPH from Boston University in Epidemiology and Biostatistics. Past research interests have included risk factors for identifying susceptibility to cancer as well as molecular prognostic indicators of disease.

“This is a remarkable time to join the Flagship Biosciences team,” said Gina. “I look forward to advancing Flagship’s award-winning solutions and stellar customer service with a world-class commercial organization. We are poised for big things and I am thrilled to be a part of Flagship’s exciting next chapter.”

To learn more about Flagship Biosciences, please visit flagshipbio.com.

About Flagship Biosciences

Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Our services and technology dramatically improve on the data and interpretation from traditional methods, eliminating variability associated with typical biomarker assessments, and bringing new insights to analysis results. We provide expert scientific consultation for every client. Our team interprets results, contextualizes biology, and identifies the best course for success. For more information, please visit flagshipbio.com and follow us on Twitter and LinkedIn.

Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.

Recent Posts

Flagship Biosciences Is Honored with a Best Practices Award

We are honored to announce that Flagship Biosciences has earned a Frost & Sullivan 2023 North American Customer Value Leadership Award in the AI-enabled digital pathology solutions market. Following from detailed evaluation of best practices criteria, the award...

Flagship Biosciences hires Tom Turi, Ph.D. as CSO

Accomplished industry executive strengthens company’s position as a leader in spatial biology and biomarker analytics.BROOMFIELD, CO - September 27, 2022 — Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the hiring...